Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases

Abstract

This review focuses on the potential of nanotherapeutics in the diagnosis and treatment of neuronal abnormal conditions particularly epilepsy, alzheimer's disease (AD), and Parkinson's disease (PD). The advancements in nanotechnology have paved the way for the development of nanocarrier systems that can target the underlying pathogenesis of these diseases. The study aimed to explore the efficacy of nanosystems in treating epilepsy, AD, and PD by analyzing relevant articles from databases such as Medline, PubMed and the national library of medicine. The review discusses the targeted delivery of active therapeutics to the central nervous system, with a focus on modulating neuronal and endothelial cell activity. It highlights various nanotherapeutic approaches, including pH-responsive nanomaterial-based therapeutics, nano-bioelectronic-implantable transient electronic devices, and electro-responsive nanosystems for the treatment of epilepsy. Additionally, the efficacy of nanodrug delivery systems loaded with curcumin, monoclonal anti-tau antibody-coated gold nanoparticles, Polyethylene Glycolpolylactide-Polyglycolide (PEG-PLGA) nanoparticles loaded with lactoferrin, dopamine-conjugated Albumin/PLGA nanosystems, and curcumin-loaded T807/RPCNP nanoparticles against neurodegeneration is discussed. The findings of this review provide valuable insights into the implications and challenges of nanotherapeutics in the field of neurological diseases. Neurologists and clinicians can benefit from this knowledge to better understand the potential applications of nanotherapeutics in the diagnosis and treatment of these conditions.